Ampio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AMPE Ampio Pharmaceuticals Inc
IKNX Ikonics Corp
UTX United Technologies Corp
KR Kroger Co
$TBK.TC iSHR LEH TIPS TC
NFLX Netflix Inc
MLM Martin Marietta Materials Inc
HUBS HubSpot Inc
SBUX Starbucks Corp
VIOT Viomi Technology Co Ltd
Go

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

Closing Price
$0.53
Day's Change
0.115 (27.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.5829
Day's Low
0.45
Volume
(Heavy Day)
Volume:
9,585,398

10-day average volume:
2,449,755
9,585,398

Sientra to Present at the 9th Annual SVB Leerink Global Healthcare Conference

5:52 pm ET February 20, 2020 (Globe Newswire) Print

Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, announced today that members of management are scheduled to present at the 9 Annual SVB Leerink Global Healthcare Conference.

 Event:  9th Annual SVB Leerink Global Healthcare Conference
 Date:   Wednesday, February 26, 2020
 Time:   11:30am ET

An audio webcast of the Company's presentation will be made available on the investor relations section of Sientra's website at http://www.sientra.com. A replay of the presentation will be available for 90 days.

About Sientra

Headquartered in Santa Barbara, California, Sientra is a diversified global medical aesthetics company and a leading partner to aesthetic physicians. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company's Breast Products Segment includes its OPUS(TM) breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2(R) breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM(R) the #1 performing, preferred and recommended scar gel of plastic surgeons. The Company's miraDry Segment, comprises its miraDry(R) system, which is approved for sale in over 40 international markets, and is the only non-invasive FDA-cleared device for the permanent reduction of underarm sweat, odor and hair of all colors.

____________________

(*) Data on file

Investor Relations
805-679-8885

https://ml.globenewswire.com/media/3d42c3fa-0850-4a26-bd85-40bafedbaecd/small/logo-no-tag-2c-jpg.jpg

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.